Institut Cochin, Université Paris Descartes (Unité Mixte de Recherche S1016), Paris, France. vincent.mallet@cch.aphp.fr
Abstract
BACKGROUND: There is currently no accepted treatment of chronic hepatitis E virus (HEV) infection.
OBJECTIVE: To report 2 patients in whom ribavirin therapy seemed to alter the natural history of chronic HEV infection.
DESIGN: Case reports.
SETTING: Hepatology unit of a tertiary care center in France.
PATIENTS: A kidney and pancreas transplant recipient and a patient with idiopathic CD4(+) T lymphocytopenia, both with biopsy-proven chronic HEV infection.
INTERVENTION: Patients received oral ribavirin, 12 mg/kg of body weight daily for 12 weeks.
MEASUREMENTS: Liver function tests, detection of HEV RNA (viremia and stool shedding) by reverse transcriptase polymerase chain reaction, and anti-HEV IgM and IgG antibodies.
RESULTS: Both patients had normalized liver function test results after 2 weeks of treatment and cleared HEV after 4 weeks of treatment. Hepatitis E virus RNA remained undetectable in the serum and stools throughout follow-up (3 months and 2 months for the first and second patient, respectively). Side effects were considered mild. Limitation: Given the relatively short follow-up, the achievement of HEV eradication could not be claimed.
CONCLUSION: Ribavirin is a potentially effective treatment of HEV infection and should be evaluated in patients with chronic HEV infection.
PRIMARY FUNDING SOURCE: None.